Govt okays 16 foreign investment proposals worth Rs 6,751 cr

Image
Press Trust of India New Delhi
Last Updated : Jun 17 2015 | 4:32 PM IST
The government today approved 16 foreign investment proposals, including those of Torrent Pharmaceuticals and Star India Private Limited, amounting to Rs 6,750.86 crore.
"Based on the recommendations of Foreign Investment Promotion Board (FIPB)... Government has approved 16 proposals of Foreign Direct Investment (FDI) amounting to Rs 6,750.86 crore," Finance Ministry said in a statement.
The proposals were cleared during the FIPB meeting held on May 28, it added.
However, a total of 21 proposals were deferred during the meeting and six others were rejected.
The government has approved Torrent Pharmaceuticals' proposal for increasing FII investment from 13.09 per cent to 35 per cent.
While, Syngene International has been allowed to raise foreign investment to 44 per cent from 10 per cent by initial public offering of equity shares to FIIs, FPIs and NRIs.
Broadcaster Star India Private Limited has been given approval for further issuance and transfer of shares to its foreign collaborator and acquisition of another Indian company engaged in broadcasting sector on a slump sale basis.
Among others, FDI proposals of Stericat Gut Strings Pvt Ltd, BASF Chemicals India Private Ltd, Ordain Health Care Global, Mumbai-based TRIF Kochi Projects, TRIF Real Estate and Development Ltd, Berggruen Real Estates and Today Magazines Lifestyle, were also approved.
Meanwhile, FDI proposal for increasing the aggregate foreign investment in Kotak Mahindra Bank to 55 per cent, pursuant to a merger between ING Vyasa and Kotak, has been deferred.
Others in deferred list include Reliance Globalcom Ltd, Bermuda, Celon Laboratories for downstream investment in another brownfield pharma company, INX Music Private Limited, Eros International Media, NTT Communications India, Hathway Cable and Datacom and DEN Networks.
Also, the government has rejected FDI proposal of Strides Arcolab for issuing shares to non-resident and resident equity shareholders of Shasun Pharmaceuticals under a merger scheme.
Proposals of SME Capital Market Corp, IIFL Holdings, Quantam Simulators, Big India Malls and Cheekotel Venture Fund were also rejected.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 17 2015 | 4:32 PM IST

Next Story